Remove Acquisition Remove Arcturus Remove Blogging Remove Development
article thumbnail

Xconomy Q&A: An Update with Arcturus Therapeutics CEO Joseph Payne

Xconomy

Things have been moving quickly in recent weeks for the San Diego RNA drug developer Arcturus Therapeutics. After initiating a reverse merger last month, Arcturus signed a research collaboration and worldwide licensing agreement with Janssen Pharmaceuticals, part of the Johnson & Johnson (NYSE: JNJ ) family of companies.